Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes.
Patients with the metabolic syndrome are insulin resistant and manifest a cluster of risk factors for cardiovascular disease. Impaired fibrinolysis and increased concentrations in blood of plasminogen activator inhibitor-1 (PAI-1) are related to insulin resistance and abdominal obesity and may contribute to the increased risk for cardiovascular disease in this group. Weight loss, metformin, and thiazolidinediones ameliorate insulin resistance and decrease concentrations of PAI-1. Thus, they may lower risk in patients with the metabolic syndrome.
Trost
Susanne
S
Diabetes and Metabolism Translational Medicine Unit, University of Vermont College of Medicine, One South Prospect Street, Burlington, VT 05401, USA. Susanne.trost@vtmednet.org
Pratley
Richard
R
Sobel
Burton
B
D000273:Adipose Tissue / Q000503:physiopathology; D050197:Atherosclerosis / Q000453:epidemiology; D001777:Blood Coagulation; D002318:Cardiovascular Diseases / Q000453:epidemiology*; D003924:Diabetes Mellitus, Type 2 / Q000503:physiopathology*; D003925:Diabetic Angiopathies / Q000453:epidemiology*; D005342:Fibrinolysis / Q000502:physiology*; D006801:Humans; D006943:Hyperglycemia / Q000503:physiopathology; D024821:Metabolic Syndrome / Q000503:physiopathology*; D017395:Plasminogen Activator Inhibitor 1 / Q000235:genetics; D012307:Risk Factors
D017395:Plasminogen Activator Inhibitor 1